ナミキ商事株式会社 医薬品及び創薬化学品の専門商社

医薬品及び創薬化学品の専門商社

検索検索

バイオ製品Bio Products

タンパク質(癌免疫療法用)

ACROBiosystems社 プロダクトリスト:Recombinant Protein

サプライヤー
AcroBioSystems
カタログNo.
GMF-H4214
製品名称
ActiveMax Recombinant Human GM-CSF
タンパク質名
GM-CSF
Species
Human
HOST
HEK293
20ug: 34,000円
お問い合わせ
50ug: 59,000円
お問い合わせ

Overview

Synonyms GM-CSF,CSF2,MGC131935
Characteristics This protein carries no "tag". The protein has a calculated MW of 14.5 kDa. The protein migrates as 16-26 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin Level Less than 0.1 EU per μg by the LAL method.
Purity >95% as determined by SDS-PAGE.
Description Granulocyte-macrophage colony-stimulating factor (GM-CSF) is also known as Colony stimulating factor 2 (granulocyte-macrophage), is a cytokine initially characterized by its ability to induce colonies of granulocytes and macrophages from myeloid progenitor cells, and is secreted by macrophages, T cells, mast cells, endothelial cells and fibroblasts. GM-CSF is a cytokine that functions as a white blood cell growth factor. GM-CSF stimulates stem cells to produce granulocytes (neutrophils, eosinophils, and basophils) and monocytes. Monocytes exitthe circulation and migrate into tissue, whereupon they mature into macrophages and dendritic cells. Thus, it is part of the immune/inflammatory cascade, by which activation of a small number of macrophages can rapidly lead to an increase in their numbers, a process crucial for fighting infection. The active form of the protein is found extracellularly as a homodimer. Human GM-CSF glycosylated in its mature form. As a part of the immune/inflammatory cascade, GM-CSF promotes Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity, and thus worthy of consideration for therapeutic target. GM-CSF has also recently been evaluated in clinical trials for its potential as a vaccine adjuvant in HIV-infected patients. The preliminary results have been promising. GM-CSF is also used as a medication to stimulate the production of white blood cells following chemotherapy.
Reference (1) Volmar, C.H. et al., 2008, Cytokine. 42(3): 336-344.
(2) Breitbach CJ, et al., 2010, Nature 477 (7362): 99?102.
(3) Korzenik J, et al., 2005, N Engl J Med 352 (21): 2193?201.
URL http://www.acrobiosystems.com/P277-Human-GM-CSF-ProteinHEK293-expressedActiveMax.html

お問い合わせリスト(-)

お問い合わせフォーム